Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12018918 | 0.94 | ACE (0.39) | HDAC1HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL23584493 | 0.94 | ACE (0.39) | HDAC1HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL10126864 | 0.94 | ACE (0.39) | HDAC1HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL13823126 | 0.94 | ACE (0.39) | HDAC1HDAC8HDAC6ALDH1A1HPGD | |
| SCHEMBL14063961 | 0.84 | HDAC1 (0.40) | HDAC1HDAC8HDAC6CYP2D6 | |
| SCHEMBL10126853 | 0.84 | HDAC1 (0.40) | HDAC1HDAC8HDAC6CYP2D6 | |
| SCHEMBL14063959 | 0.84 | HDAC1 (0.40) | HDAC1HDAC8HDAC6CYP2D6 | |
| SCHEMBL1355665 | 0.84 | HDAC1 (0.40) | HDAC1HDAC8HDAC6CYP2D6 | |
| SCHEMBL12018877 | 0.84 | HDAC1 (0.40) | HDAC1HDAC8HDAC6CYP2D6 | |
| SCHEMBL10126851 | 0.84 | HDAC1 (0.40) | HDAC1HDAC8HDAC6CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220296581-A1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2022-09-22 | — | — | US | disclosed |
| US-11382905-B2 | Immunomodulation by IAP inhibitors | NOVARTIS AG (CH) | 2022-07-12 | — | — | US | disclosed |
| EP-2698158-B1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2021-06-30 | — | — | EP | disclosed |
| US-20200345714-A1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2020-11-05 | — | — | US | disclosed |
| US-10786491-B2 | Immunomodulation by IAP inhibitors | NOVARTIS AG (CH) | 2020-09-29 | — | — | US | disclosed |
| EP-3701947-A1 | IMMUNOMODULATION BY IAP INHIBITORS | Novartis AG (CH) | 2020-09-02 | — | — | EP | disclosed |
| EP-2296650-B1 | IMMUNOMODULATION BY IAP INHIBITORS | NOVARTIS AG (CH) | 2020-05-06 | — | — | EP | disclosed |
| US-10329626-B2 | NOL3 is a predictor of patient outcome | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20170368047-A1 | Immunomodulation by IAP Inhibitors | NOVARTIS AG (CH) | 2017-12-28 | — | — | US | disclosed |
| US-9750729-B2 | Immunomodulation by IAP inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-09-05 | — | — | US | disclosed |
| EP-2296650-A1 | IMMUNOMODULATION BY IAP INHIBITORS | Novartis AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| EP-2253614-A1 | Inhibitors of IAP | Novartis AG (CH) | 2010-11-24 | — | — | EP | disclosed |
| US-20100179163-A1 | NOL3 IS A PREDICTOR OF PATIENT OUTCOME | DANA-FARBER CANCER INSTITUTE, INC. | 2010-07-15 | — | — | US | disclosed |
| WO-2009140447-A1 | IMMUNOMODULATION BY IAP INHIBITORS | NOVARTIS AG (CH) | 2009-11-19 | — | — | WO | disclosed |
| EP-2065368-A1 | Inhibitors of IAP | Novartis Ag (CH) | 2009-06-03 | — | — | EP | disclosed |
| US-20080242658-A1 | Inhibitors of Iap | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| US-7419975-B2 | Organic compounds | NOVARTIS AG (CH) | 2008-09-02 | — | — | US | disclosed |
| EP-1735307-A1 | INHIBITORS OF IAP | Novartis AG (CH) | 2006-12-27 | — | — | EP | disclosed |
| US-20050234042-A1 | Organic compounds | PALERMO MARK G | 2005-10-20 | — | — | US | disclosed |
| WO-2005097791-A1 | INHIBITORS OF IAP | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242658-A1 | Inhibitors of Iap | XIAP, BIRC2, BIRC5 | HDAC1 1305/4885HDAC8 2249/4885HDAC6 2280/4885 |
| US-20220296581-A1 | Immunomodulation by IAP Inhibitors | BIRC2, BIRC3, BIRC5 | HDAC1 2168/4885HDAC8 1557/4885HDAC6 1895/4885 |
| US-10786491-B2 | Immunomodulation by IAP inhibitors | BIRC2, BIRC3, BIRC5 | HDAC1 2168/4885HDAC8 1557/4885HDAC6 1895/4885 |
| US-20170368047-A1 | Immunomodulation by IAP Inhibitors | BIRC2, BIRC3, BIRC5 | HDAC1 2168/4885HDAC8 1557/4885HDAC6 1895/4885 |
| US-11382905-B2 | Immunomodulation by IAP inhibitors | BIRC2, BIRC3, BIRC5 | HDAC1 2168/4885HDAC8 1557/4885HDAC6 1895/4885 |
| US-20200345714-A1 | Immunomodulation by IAP Inhibitors | BIRC2, BIRC3, BIRC5 | HDAC1 2168/4885HDAC8 1557/4885HDAC6 1895/4885 |
| US-20050234042-A1 | Organic compounds | AIFM1, BAX, API5 | HDAC1 877/4885HDAC8 2270/4885HDAC6 2209/4885 |
| US-10329626-B2 | NOL3 is a predictor of patient outcome | MORF4L1, NOS3, NOS1 | HDAC1 3936/4885HDAC8 3889/4885HDAC6 4088/4885 |
| US-20100179163-A1 | NOL3 IS A PREDICTOR OF PATIENT OUTCOME | MORF4L1, NOS3, NOS1 | HDAC1 3936/4885HDAC8 3889/4885HDAC6 4088/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.